



Press release

Valby, 30 November 2023

Lundbeck R&D Event to showcase innovative pipeline

H. Lundbeck A/S (Lundbeck) is hosting an R&D Event in London today, providing analysts and investors with an update on the progress of its R&D transformation.

Today, Lundbeck is hosting an investor R&D Event in London, offering insights into the company's commitment to leveraging its transformed R&D pipeline for future growth.

The event will feature Lundbeck's CEO Charl van Zyl, Head of R&D Johan Luthman, and other R&D leaders.

Lundbeck experienced significant R&D milestones in 2023, securing two FDA approvals, eight key headline results, a phase II proof of concept with a novel mechanism of action, and five new entries into the research pipeline.

Lundbeck is strategically focused on neuroscience; a therapy area that is currently experiencing significant scientific and therapeutic breakthroughs and thereby is poised for major growth. In recent years, Lundbeck has transformed its R&D organization and strategy and built an innovation pipeline of first-in-class, breakthrough potential, programs.

Lundbeck's R&D has, in parallel, been conducting impactful life cycle management activities that expand current brands. Through this, Lundbeck is growing its business and is well-positioned for future commercial success.

The R&D Event will cover these changes and provide a spotlight on examples of pipeline programs that exemplify the future path of the company.

The event will be webcast live on November 30, 2023, at 12:30 PM GMT. Please to go the Investors section of Lundbeck.com at [Lundbeck.com/global/investors](https://www.lundbeck.com/global/investors)

All sessions of the R&D Event are webcast live, and a replay will be made available on the Investors section of Lundbeck.com. Presentation material from the R&D Event will also be available in the Investors section of Lundbeck.com.

Contacts

Thomas Mikkel Mortensen
Media Relations Lead, Corp. Communication
THMR@lundbeck.com
+45 30 83 30 24

Palle Holm Olesen
Vice President, Investor Relations
PALO@lundbeck.com
+45 30 83 24 26



About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research.

We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via [LinkedIn](#).